I'm not going to try and defend the last 10 years but what I do know is that AFREZZA is a NEW THERAPY for treating diabetes. Therefore there will be a LEARNING CURVE in understanding the product from the doctors viewpoint, the patients and the insurance companies. That covers all aspects on the product which includes DOSING, Marketing, Distribution, Education, etc.
Afrezza is not like ORALS MEDS where you take pills and see what happens. I'm sure when Injectables hit the market there was a HUGE LEARNING CURVE and I'm sure a lot of diabetics were having difficulty with HYPOS, HYPERS and especially STACKING until they learned the correct dosing.
Then you have to be concerned about BIG PHARMA with their POWER and INFLUENCE to squash Afrezza and Mannkind. You can bet they are pulling out all the stops and calling in ALL FAVORS to kill Afrezza. So that's an obstacle they have to deal with.
It's going to take time. There will be insurance problems, there will be training problems and there will be company problems but as long as they are making progress and the trend of scripts continue to climb everything will be fine.
The early stage problems MNKD faces are FIXABLE.
They are building out their salesforce, applying for a better label, starting a PEDS Trial, and working on better insurance coverage and putting money into a small DTP Campaign.
It's going to take time and patience.
News 
Market Data 
Discover 
